T. S. K. Mok Et Al. , "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial," LANCET , vol.393, no.10183, pp.1819-1830, 2019
Mok, T. S. K. Et Al. 2019. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. LANCET , vol.393, no.10183 , 1819-1830.
Mok, T. S. K., Wu, Y., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., ... Castro, G.(2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. LANCET , vol.393, no.10183, 1819-1830.
Mok, Tony Et Al. "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial," LANCET , vol.393, no.10183, 1819-1830, 2019
Mok, Tony S. Et Al. "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial." LANCET , vol.393, no.10183, pp.1819-1830, 2019
Mok, T. S. K. Et Al. (2019) . "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial." LANCET , vol.393, no.10183, pp.1819-1830.
@article{article, author={Tony S. K. Mok Et Al. }, title={Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial}, journal={LANCET}, year=2019, pages={1819-1830} }